,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'destiny-breast04']
presented at the #asco22 plenary session, the destiny-breast04 trial demonstrates t-dxd treatment leads to improvements in progression-free survival, overall survival for patients with her2-low #metastatic #breastcancer 1/3 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ